"We're Doomed, We're Saved" with Andreas Horchler and Louise von Stechow – father and daughter, journalist and biologist, talking about the technologies of the biorevolution. Can genetic engineering, synthetic biology, and artificial intelligence save humanity from disease, climate change, and overpopulation, or are these technologies the first step towards its downfall? Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics but do not claim to give medical, investment, or life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Image: Kelly Sikkema via Unsplash
https://science-tales.com/
We are doomed we are saved #18
Ozempic & co – a new era of weight loss?
In principle the solution to the problem of overweight should be very easy: eat less and exercise more.But anyone who’s ever tried to lose weight – so probably almost anyone – will be able to testify that things are not as simple. So now Ozempic enters the scene, a diabetes drug that looks like a gamechanger in the big business of weight loss. In episode 18 of We're doomed we're saved, Andreas Horchler and Louise von Stechow discuss the history of weight loss pills and the medical and cultural reasons why we (think we) need to be thin.
Content and Editing: Louise von Stechow and Andreas Horchler
Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Image: Nathan Dumlao- via Unsplash
References: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 https://www.nytimes.com/2023/08/28/business/denmark-ozempic-wegovy.html https://www.nature.com/articles/d41591-023-00075-x https://www.nature.com/articles/s41573-021-00337-8 https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists